Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success

Area of Science:

• Oncology
• Pharmacology

Background:

• Activating BRAF mutations are key drivers in various malignancies.
• Targeted therapies have revolutionized treatment paradigms for BRAF-mutated cancers.

Purpose of the Study:

• To review recent therapeutic advancements in BRAF-mutant tumor treatment.
• To discuss common adverse events associated with BRAF-targeted agents.
• To suggest strategies for managing treatment-related toxicities.

Main Methods:

• Literature review of recent studies on BRAF and MEK inhibitors.
• Analysis of clinical trial data for efficacy and safety outcomes.
• Synthesis of information on adverse event profiles and management strategies.

Main Results:

• BRAF and MEK inhibitors show significant anti-tumor efficacy in BRAF-mutated malignancies.
• Dual MAPK inhibition is a key strategy demonstrating therapeutic benefits.
• While generally well-tolerated, these agents can cause variable side effects across organ systems.

Conclusions:

• BRAF and MEK inhibitors represent a major therapeutic advance for BRAF-mutant cancers.
• Understanding and managing the specific adverse events of these targeted agents is critical for optimal patient care.